Ipamorelin vs NAD+

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates pulsatile GH release from the anterior pituitary with high selectivity — producing minimal effect on cortisol, prolactin, or ACTH compared to earlier GHRPs. It is commonly researched for its role in supporting body composition, recovery, and lean mass maintenance.

NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell, central to energy production, DNA repair, and sirtuin activation. While not a peptide in the traditional sense, it is widely administered by functional medicine and longevity providers via intravenous infusion or subcutaneous injection. Research interest centres on its role in mitochondrial health, cellular resilience, and neurological function as NAD+ levels decline with age.